riociguat PAH
Selected indexed studies
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (JAMA, 2022) [PMID:35412560]
- Pulmonary Hypertension: A Brief Guide for Clinicians. (Mayo Clin Proc, 2020) [PMID:32861339]
- Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. (Lancet Respir Med, 2021) [PMID:33773120]
_Worker-drafted node — pending editorial review._
Connections
riociguat PAH is a side effect of
Sources
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (2022) pubmed
- Pulmonary Hypertension: A Brief Guide for Clinicians. (2020) pubmed
- Update of EULAR recommendations for the treatment of systemic sclerosis. (2017) pubmed
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis. (2024) pubmed
- New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. (2025) pubmed
- New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (2024) pubmed
- Riociguat: Clinical research and evolving role in therapy. (2021) pubmed
- Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension. (2022) pubmed
- Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. (2021) pubmed
- Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study. (2021) pubmed